Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Strongyloidiasis in immigrants and refugees in Canada

Courtney Thompson and Andrea K. Boggild
CMAJ December 08, 2015 187 (18) 1389; DOI: https://doi.org/10.1503/cmaj.141441
Courtney Thompson
Department of Medicine (Thompson, Boggild), University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario; Tropical Disease Unit (Boggild), Division of Infectious Diseases, Toronto General Hospital, University Health Network, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea K. Boggild
Department of Medicine (Thompson, Boggild), University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario; Tropical Disease Unit (Boggild), Division of Infectious Diseases, Toronto General Hospital, University Health Network, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: andrea.boggild@utoronto.ca
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Strongyloidiasis is a potentially life-threatening infection caused by the soil-transmitted helminth Strongyloides stercoralis

Strongyloides stercoralis is an intestinal roundworm transmitted primarily through barefoot skin exposure in the tropics or subtropics. Acute infection may present with papular rash, cough or wheezing, and gastrointestinal symptoms.1 Manifestations of chronic infection are present in up to half of infected patients and may include abdominal pain, diarrhea, vomiting, recurrent asthma, a Löffler-like syndrome, larva currens (Figure 1) or pruritis ani. Eosinophilia may be absent.

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

Larva currens rash of strongyloidiasis.

Screening for strongyloidiasis is recommended in Canada for refugees from Southeast Asia and Africa and is strongly suggested for immigrants from endemic countries

Global estimates of prevalence suggest that strongyloidiasis affects up to 40% of the population in the tropics and subtropics.2 It is estimated to affect 9%–77% of immigrants and refugees in Canada, with highest prevalence among those from Southeast Asia.3 Endemic regions include South America, Africa, Southeast Asia and the Caribbean.

Without treatment, strongyloidiasis is a lifelong infection

Autoinfection is a unique feature of S. stercoralis enabling lifelong persistence, potentially for decades after immigration.1 Larvae passed in the stool are capable of re-infecting humans.1 Suspicion of chronic strongyloidiasis rests upon the epidemiologic history, as most patients are asymptomatic. Active screening and treatment of at-risk groups eradicates infection and eliminates the risk of future severe complications, including death. Persons at risk should be screened with serologic tests (enzyme immunoassay), which are highly sensitive.4 Though definitive for diagnosis, demonstration of parasites in stool is an insensitive test. Serologic testing is performed at reference laboratories, including the National Reference Centre for Parasitology in Montréal (www.medicine.mcgill.ca/tropmed/txt/services.htm#STRONGLYOIDIASIS).

Disseminated strongyloidiasis is a complication with high mortality

Dissemination involves widespread migration of larvae to multiple organ systems. Bacteremia can result from gut translocation, as larvae exit the gut and migrate through tissue.1 The case-fatality rate is at least 68.5% (100% if untreated).5 Risk factors for dissemination include immunosuppression by oral glucocorticoids, human T-cell lymphotrophic virus type I infection, bone marrow or solid organ transplant, hypogammaglobulinemia and malnutrition. Patients with a history of travel to or previous residence in an endemic country should be screened before initiation of any immunosuppression, including short courses of steroids.

In Canada, medication to treat strongyloidiasis is available only through the Special Access Programme of Health Canada

Ivermectin (200 μg/kg) given as a single dose and repeated two weeks later is the treatment of choice for simple intestinal strongyloidiasis, including asymptomatic infections, and is more than 95% effective.5 Management of strongyloidiasis, particularly disseminated disease, should be performed in consultation with an expert in migrant health or tropical infectious diseases.

Footnotes

  • Competing interests: Andrea Boggild is a member of the Committee to Advise on Tropical Medicine and Travel, an external advisory body to the Public Health Agency of Canada. No other competing interests were declared.

  • This article has been peer reviewed.

References

  1. ↵
    1. Greaves D,
    2. Coggle S,
    3. Pollard C,
    4. et al
    . Strongyloides stercoralis infection. BMJ 2013;347:f4610.
    OpenUrlFREE Full Text
  2. ↵
    1. Schär F,
    2. Trostdorf U,
    3. Giardina F,
    4. et al
    . Strongyloides stercoralis: global distribution and risk factors. PLoS Negl Trop Dis 2013;7:e2288.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Pottie K,
    2. Greenaway C,
    3. Feightner J,
    4. et al
    . Evidence-based clinical guidelines for immigrants and refugees. CMAJ 2011;183:E824–925.
    OpenUrlFREE Full Text
  4. ↵
    1. Bisoffi Z,
    2. Buonfrate D,
    3. Sequi M,
    4. et al
    . Diagnostic accuracy of five serologic tests for Strongyloides stercoralis infection. PLoS Negl Trop Dis 2014;8:e2640.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Suputtamongkol Y,
    2. Premasathian N,
    3. Bhumimuang K,
    4. et al
    . Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. PLoS Negl Trop Dis 2011;5:e1044.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 187 (18)
CMAJ
Vol. 187, Issue 18
8 Dec 2015
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Strongyloidiasis in immigrants and refugees in Canada
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Strongyloidiasis in immigrants and refugees in Canada
Courtney Thompson, Andrea K. Boggild
CMAJ Dec 2015, 187 (18) 1389; DOI: 10.1503/cmaj.141441

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Strongyloidiasis in immigrants and refugees in Canada
Courtney Thompson, Andrea K. Boggild
CMAJ Dec 2015, 187 (18) 1389; DOI: 10.1503/cmaj.141441
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Strongyloidiasis is a potentially life-threatening infection caused by the soil-transmitted helminth Strongyloides stercoralis
    • Screening for strongyloidiasis is recommended in Canada for refugees from Southeast Asia and Africa and is strongly suggested for immigrants from endemic countries
    • Without treatment, strongyloidiasis is a lifelong infection
    • Disseminated strongyloidiasis is a complication with high mortality
    • In Canada, medication to treat strongyloidiasis is available only through the Special Access Programme of Health Canada
    • Footnotes
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Chronic cutaneous ulcer from drug use
  • A low-barrier, flexible safe supply program to prevent deaths from overdose
  • Digital gangrene in a woman with scleroderma
Show more Practice

Similar Articles

Collections

  • Sections
    • Five Things to Know About
  • Topics
    • Drugs: antimicrobials
    • Global health
    • Infectious diseases
    • Screening & diagnostic tests

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire